Ticker Hub
LGND — AI Analysis & Sentiment
3 recent AI-generated analyses for LGND. Sentiment and confidence insights updated continuously.
Ligand Reports First Quarter 2026 Financial Results
Ligand reported strong Q1 results with significant royalty revenue growth and reaffirmed its full-year guidance, driven by key assets and the pendi...
May 7, 2026Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand's acquisition of XOMA Royalty is a significant strategic move expected to boost earnings and expand its diversified royalty portfolio. This ...
Apr 27, 2026Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
Full FDA approval for FILSPARI in FSGS expands the market for a key royalty-generating drug, enhancing Ligand's future revenue and long-term growth...
Apr 14, 2026